

**LungLife AI, Inc.**  
(the "Company" or "LungLife")

**Notice of Results**  
*Investor Briefing*

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2024 on Thursday 22 August 2024.

**Investor presentation**

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the half-year report via the Investor Meet Company platform at 5pm (BST) on Thursday 22 August 2024.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am (BST) the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet LUNGLIFE AI, INC via:

<https://www.investormeetcompany.com/lunglife-ai-inc/register-investor>

Investors who already follow LUNGLIFE AI, INC on the Investor Meet Company platform will automatically be invited.

A recording of the presentation and a PDF of the slides used will also be available on the LungLife website:  
<https://lunglifeai.com/investors/>

**For further information please contact:**

**LungLife AI, Inc.**  
Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)  
[investors@lunglifeai.com](mailto:investors@lunglifeai.com)

**Investec Bank plc (Nominated Adviser & Joint Broker)**  
Virginia Bull / Lydia Zychowska / Sara Wallace

Tel: +44 (0)20 7597 5970

**Goodbody (Joint Broker)**  
Tom Nicholson / Cameron Duncan

Tel: +44 (0) 20 3841 6202

**About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB<sup>®</sup> test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORSFAFALELSEEA